ProfileGDS5678 / 1439518_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 86% 83% 83% 83% 67% 75% 73% 78% 83% 88% 81% 77% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.4223786
GSM967853U87-EV human glioblastoma xenograft - Control 26.533386
GSM967854U87-EV human glioblastoma xenograft - Control 36.031383
GSM967855U87-EV human glioblastoma xenograft - Control 46.2577383
GSM967856U87-EV human glioblastoma xenograft - Control 56.1011483
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0685867
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8308875
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6788573
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3444978
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1568683
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8192988
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.8160181
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1855777
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3815885